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 Nanotechnology has the potential to profoundly change our standard of living and 
world economy. Its impact is expected to be deeper than the impact information 
technology has had over individual and collective lives over the past decades.2 
Worldwide there is a widespread belief among the political and scientific communities 
that the nanotechnology industrial wave will bring changes to the world development and 
economic power status quo, as these technologies are expected to grant competitive 
advantage to the economies that first master them. In this sense, the EU Commission has 
expressed concerns of losing competitiveness should it fail to keep pace with other 
economies in the development of nanotechnology. 3 
 There is also the perception that direct investment in Nanoscience research is not 
enough and special attention need to be drawn to intellectual property (IP) rights and 
especially patent law, as it will play a central role in the outcome of general policies 
directed towards promoting innovation and technological based economic growth. In this 
context the patent system is understood as a tool to promote not only innovation and 
scientific research, but also technology transfer from research entities to industry.4 
However, it can be debated if in practice the current European patent framework is in fact 
promoting innovation to the full extent of its possibilities. This article focuses on the 
specific example of nanotechnology inventions and the methods for treatment and 





 Nanoscience advances can lead to progress in virtually all technological sectors, 
and for this reason this scientific field is often characterized as being an horizontal, key 
or enabling science. Nanotechnology is also described as a converging technology in the 
sense that it brings together different areas of science, thus the term is often referred to 
                                                 
1 This article is based on the author’s thesis ‘Nanotechnology Patents in Europe: Exclusions and Exceptions 
to Patentability’, written as part of the Master’s Programme in European Intellectual Property Law, 
Stockholm University, 2009. The Author wishes to express her gratitude to Åsa Hellstadius, doctoral 
candidate at Stockholm University for proofreading this article and for her comments and advice. 
2 Hullman, A. The economic development of nanotechnology – An indicators based analysis, 2006, 
European Commission Unit: Nano S&T – Convergent Science and Technologies. Available at: 
http://cordis.europa.eu/nanotechnology (November 2009). 
3 See Communication from the Commission to the Council, The European Parliament and The Economic 
and Social Committee, ‘Nanosciences and nanotechnologies: An action plan for Europe 2005-2009’, 
Brussels, 7.6.2005 (COM (2005) 243 final). 
4 ‘Nanosciences and nanotechnologies: An action plan for Europe 2005-2009’, Brussels, 7.6.2005 
(COM(2005) 243 final). 
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as an umbrella designation encompassing a vast range of technologies that manipulate 
matter at nanoscale which means building structures and new materials at an atomic, 
molecular and macromolecular scale. Any definition of nanotechnology must necessarily 
be used with caution, being an emerging technological area at the present moment the 
exact meaning of the term ‘nanotechnology’ is still subject to intense debate among the 
scientific community, starting with questioning whether the term should or not be used 
in the plural form.5 For the purposes of this article the following definition, issued by the 
European Patent Office will be used:  
 
‘The term nanotechnology covers entities with a controlled geometrical size of 
at least one functional component below 100 nanometers in one or more 
dimensions susceptible of making physical, chemical or biological effects 
available which are intrinsic to that size. It covers equipment and methods for 
controlled analysis, manipulation, processing, fabrication or measurement with 
a precision below 100 nanometres.’6 
3. Nano-medicine and the Methods for treatment and diagnostic exception  
 
 Nano-medicine research has shown very promising results and an enormous 
potential to provide solutions in the nearby future to humanise health-care, increase the 
quality of life, and promote full integration in society of people suffering from long term 
or incurable medical conditions. The convergence of nanotechnology with 
biotechnology, biomedicine, and information and communication technologies is 
expected to lead to great advances in prosthetics, organ replacement and reconstruction 
surgery, in addition advances provided by nanotechnology will also significantly 
improve the ability to detect and diagnose disease by introducing small, highly sensitive, 
inexpensive devices for the manipulation and analysis of cells. Novel nanomaterials and 
surface modification methods have improved existing techniques that enable scientists to 
observe and analyse intracellular operations in real time. Such improvement in the study 
of cellular functions is helping researchers to detect and study diseases at a very early 
stage, and will prove instrumental to find suitable cures. 
 Examples of advanced applications of nanotechnology include the use of 
quantum dots for imaging (visualize alterations in human organs or tissue); the use of 
carbon nanotube based glucose sensors to monitor diabetes and other diseases, since they 
change infrared fluorescence according to the glucose level; miniaturised subcutaneous 
chips continuously monitoring key body parameters including pulse, temperature and 
blood glucose that could be implanted in patients or even healthy persons in order to 
achieve early diagnosis; and implantable sensors that can also interface with nanodevices 
that administer treatments automatically if needed, e.g. drug dispense systems.7 
                                                 
5 Seear, K, Prof. Petersen, A. and Bowman, D. ‘The Social and Economic Impacts of Nanotechnologies:A 
Literature Review’, Final Report Prepared for the Department of Innovation, Industry, Science and 
Research, February 2009, Monash University Victoria, Australia. The authors of this study have identified 
eighteen substantially different definitions of nanotechnology in relevant sources. 
6 In http://www.epo.org/topics/issues/nanotechnology.html (February 2010). 




Nanoparticle delivery systems or nano carriers have many advantages over traditional 
active agents n particular in the treatment and diagnosis of medical conditions such as 
cancer, diabetes and HIV/AIDS.  
 Many of the technologies being developed in the present blur the line between 
non-patentable methods for treatment and diagnostic methods practiced on the human 
body on one side and patentable products (substances or compositions) and apparatus 
used in such activities on the other. Some of these important developments in diagnostics 
and treatment operate totally in vitro, others entirely in vivo, some have a combination of 
phases in vitro and  in vivo, posing  patentability questions concerning the patentability 
exception for methods for treatment and diagnostic that require careful consideration. 
 
3.1 Nature and ratio of the Exception 
 
 Currently, the European Patent Convention (EPC) in its Article 53(c) establishes 
that: 
 ‘European patents shall not be granted in respect of: […]methods for 
treatment of the human or animal body by surgery or therapy and diagnostic 
methods practised on the human or animal body; this provision shall not apply 
to products, in particular substances or compositions, for use in any of these 
methods.‘.8  
 
 However the exception to patentability of methods for treatment and diagnostic 
pre-dates the EPC, in fact similar rules existed in a large number of European national 
jurisdictions even if under general clauses and/or by means of the practice of national 
patent offices and jurisdictional interpretation.9 Despite its long existence the ratio of the 
prohibition has never been consensual as there are several divergent currents of opinion 
concerning the subject, namely that the prohibition is based on either: (1) general clauses 
of ‘ordre public’ and morality; (2) lack of industrial application; (3) lack of an invention 
in the sense of a technical solution to a technical problem; (4) public interest 
consubstantiate in public health considerations and the deontological nature of the 
doctor-patient relation; (5) nature of the medical profession in itself that is exempted from 
commercial rules such as economic and competition considerations, since the diagnostic 
and therapeutic freedom should not be hampered by the commercial considerations that 
are subjacent to IP rights protected subject-matter.10 In the 1973 EPC the rule was inserted 
in Article 52 (4), a legal provision devoted to subject-matter that could not be considered 
as an invention and therefore impossible to patent.  The Conference of Munich of 1973, 
that approved the EPC, adopted the writing proposed by the German delegation based on 
the opinion of the BGH that considered such methods unsusceptible of industrial 
application since the medical profession by nature is not a commercial or industrial 
                                                 
8 Article 53 (c) European Patent Convention (2000). 
9 The subject was debated in particular within jurisdictions with an Anglo-Saxon legal tradition. For a 
cross-jurisdition comparative history of the prohibition see Marques, J.P Remédio ‘A patentabilidade dos 
métodos de diagnóstico, terapêuticos e cirúrgicos: Questão (bio)ética ou questão técnica? - O actual 
estado do problema’ in Estudos de Direito da Bioética, vol. II, Almedina, Coimbra, 2008. 
10 Marques, J.P Remédio op. cit.. 
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activity11 since under German doctrine and jurisprudence such activities are perceived as 
having as primary goal the profit while the medical professional sole purpose and 
objective is to serve the public interest (to cure the patient).12  
 This reference to a by default fictio juris of lack of industrial application present 
in the EPC 1973 version meant that such subject–matter had to be considered an 
invention, but on the other hand the title and body of the Article referred to subject-matter 
that could not be considered an invention and for that reason non-patentable. This 
systematization problem raised objections and difficulties of interpretation of the nature 
of the patentability prohibition. In the EPC 2000 revision this rule was moved to Article 
53 (c) and the reference to lack of industrial application deleted. The preparatory 
documents acknowledge both that the previous exclusion was an artificial legal 
construction and that these methods should be considered inventions. It is mentioned that 
the ratio for the prohibition lays in the interest of public health a category pertinent to the 
general ‘ordre public’ exemption. In addition, the need to obtain correspondence between 
the EPC and Article 27 (3) (a) of the TRIPS Agreement is also recognized as a 
motivation.13 
 
3.2 The legal regime of the exception 
 
 The scope of the exception does not include all medical methods for treatment, 
but merely (1) methods of treatment by therapy or surgery and (2) diagnostic methods 
that are (3) practiced on the human or animal body. Substances or compositions are 
expressly excluded from the prohibition.14 Apparatus claims are excluded by nature15 
thus patents may be granted for surgical, therapeutic or diagnostic instruments or any 
apparatus for use in methods for such.16 
 Therapeutic methods applied to plants, deceased human or animal bodies or 
applied to prosthetics that are not permanently attached to the body17 are also not included 
in this provision. However the exception applies to therapeutic methods applied to 
prosthetics permanently attached to the body even if the contact with the body is 
external.18  
 
                                                 
11 BGH decision in Clatzenoperation, 26/09/1967, in Gewerlicher Rechtsschutz und Urheberrecht, 1968, 
p. 142. 
12 German Federal Patent Court in ‘Haarwatchstum’ of 27/09/84 in Gewerlicher Rechtsschutz und 
Urheberrecht, 1985, p.125. According to this ruling commercial or industrial activity is an economic 
activity that pursues profit. The medical activity while being an economic activity has as final goal to serve 
public interest – to cure. More recently, in ‘Endoprotheseinsatz’ in Gewerlicher Rechtsschutz und 
Urheberrecht , 2001, p. 321 the lack of industrial application of these inventions was held as reason for 
patentability refusal., in Marques, J. op.cit.. 
13 Special edition n.4 OJ EPO 2001. 
14 Article 53(c) EPC 2000.  For simplicity reasons all future references will be used in a large sense 
including both methods for animal and human treatment. 
15 T-712/93 Joint Medical Products/Ball and socket bearing for artificial joint [1997.04.14]. 
16 EPO Guidelines Part C, Chapter IV, 4.8. 
17 T-24/91 Thompson/Cornea, OJ EPO 1991, 512.  
18 T-1077/93 L’Oreal, OJ EPO 1997, 546. 
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a) Diagnostic Methods 
 
 The meaning of this expression has always been highly debated with particular 
emphasis in situations where not all phases of the proceeding where practiced in contact 
with the human body, ultimately leading to opposite currents of jurisprudence within the 
EPO.  On one side was the line of reasoning for the first time proposed in the Brucker 
case19 and on the other side the arguments of the leading case Cygnus.20 
 In the Brucker case the EPO Technical Board of Appeal (from hereafter TBA) 
held a narrow interpretation of the prohibition, ruling that patentability should only be 
denied for methods where all the steps involved in making a medical diagnosis (making 
a decision on a particular course of medical treatment) where practiced on the human 
body. While in the later case Cygnus the TBA departed from this understanding and held 
that the expression ‘diagnostic methods practiced on the human or animal body’ should 
be considered as to relate to all methods practiced on the human or animal body which 
related to diagnosis or were of value for the purpose of diagnosis. In light of this decision, 
in order to fall within the scope of the prohibition it was enough that the claimed method 
comprised one single step which served diagnostic purposes or related to diagnosis and 
was to be regarded as an essential activity pertaining to diagnosis and practiced on the 
living human or animal body. 
 In the face of conflicting decisions and in the interest of legal certainty the 
Enlarged Board of Appeal (EBA) was called to pronounce itself over such divergence.21 
In G-1/04 the EBA took a point of view similar to the line of reasoning in Brucker.  The 
EBA held that whilst the surgical or therapeutic nature of a method claim can be 
established by a single method step, diagnostic methods have an inherent multi-step 
nature and have to be executed in several steps, cycles or activities in order to be 
considered as such within the meaning of Article 53(c) EPC.22 The EBA also 
acknowledged that methods for diagnostic imply several different phases: (1) 
examination phase translated in the gathering of data and samples, (2) comparing the data 
with reference values (3) identifying the existence or not of any significant deviation 
from reference values, i.e. identifying symptoms (4) relate eventual deviation from 
reference values (symptoms) with a certain clinical condition. According to the EBA, 
this last phase is merely deductive and constitutes an intellectual exercise that can not be 
considered an invention by itself.23 
 According to this understanding, only the first three phases are to be considered 
under the exception since only those are of a technical nature. It also implies that while 
examining a claim it is necessary to establish which of the method steps described that 
have technical character and to ascertain whether an interaction with the human or animal 
                                                 
19 T-385/86 Brucker/Non-invasive determination of measure values [1987.09.25], OJ EPO 1988, 308. 
20 T-964/99 Cygnus/Device and method of sampling of substances using alternative polarity [2001.06.29], 
OJ EPO 2002, 2. 
21 G-1/04 [2005.12.16], OJ EPO 2006, 334. 
22 G-1/04, paragraph 5. Note: This decision pre-dates the EPC 2000 revision and naturally still refers to 
Article 52(4) EPC. 
23 G-1/04, paragraph 5.2 and 6.4.1. 
Nanotechnology patents in Europe and the methods for treatment and diagnostic 
exception to patentability 
6 
body takes place.24 If all the technical phases indispensable to obtain a complete 
diagnosis (phases 1 to 3) are executed on the living body the method will be unpatentable. 
On the contrary if one of these technical phases or steps is executed but not in contact 
with the human body, the method is patentable.  
 The EBA pointed out that the fact that one step is executed in contact with the 
body e.g. gathering of samples, does not allow a complete diagnosis. Therefore it can not 
be considered a method for diagnosis but at best a method of data acquisition or data 
processing over the physical or psychic condition of (des) equilibrium of the examined 
individual and is thus patentable as such.25 
 
b) Methods of treatment /diagnostic – qualification as such 
 
 In a certain line of jurisprudence the qualification of a method of diagnosis has 
depended on the qualification of the person who was to perform it operate it, i.e. a 
physician.26  However in G-1/04 the EBA held that patentability should not be decided 
on basis of the qualification of the person who is to perform the method. The decision 
was partly based on the fact that the preparatory works of the Munich conference did not 
contain any such reference and partly on reasons pertaining to legal certainty. The Board 
held that the medical profession and medical acts are regulated differently in different 
jurisdictions and that different legal systems have different solutions regarding what 
methods and proceedings are reserved to physicians or practiced by nurses, radiologists 
technicians or other health practitioners. Thus any interpretation that makes patentability 
dependent on the professional qualification of the person who would/could perform it 
would ultimately lead to legal uncertainty.27 
 According to this legal reasoning the qualification of the person who is to perform 
it (medical physician or a veterinary) is indifferent to the qualification of a method as a 
method for treatment or for diagnosis. 
 
c) Methods of treatment by therapy v. cosmetic methods 
 
 Regarding the distinction between what can be considered therapeutic or non-
therapeutic, e.g. cosmetic, the EPO jurisprudence has applied a broad concept of 
therapeutic method.28 A method is to be considered therapeutic if its execution has the 
objective of re-establish the physical or psychic equilibrium of a person, even if such 
method is of prophylactic nature29 involving the prevention of diseases or any 
                                                 
24 See also EPO guidelines for examination Part C, Chapter IV, 4.8. 
25 G-1/04, paragraph 6.2.2. 
26 T-385/86 Brucker/Non-invasive determination of measure values, OJ EPO 1988, 308. 
27 G-1/04 Paragraph 6.1 and 6.3. 
28 In this sense see Cook, Trevor ‘Pharmaceuticals Biotechnology and the Law’, 2 ed., Lexisnexis, London 
2009. 
29 T-19/84 Duphar/Pigs II [1987.10.15], OJ EPO 189, in this decisions the TBA stated that ‘All prophylaxis 
serves to maintain health and therefore comes under the provision‘, p. 24. 
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dysfunction (such as method for removing plaque from teeth30 or hair loss31), the concept 
also includes any methods destined to relief or suppress pain, physical discomfort32 or 
restore any body functions or capabilities33 even if the diminishing was not caused by a 
disease.34 Inventions of process for artificial insemination,35 contraception36 and 
pregnancy termination are not considered therapeutically methods, since pregnancy is a 
natural state and not a disease. However, methods to prevent or cure any diseases that 
may occur during the pregnancy but are not intrinsically related to it may be considered 
therapeutic.  
 Claims to methods that have both therapeutic and cosmetic features are usually 
regarded as pertaining to therapeutic methods. Only when it is possible to autonomously 
dissociate and evaluate the cosmetic effects from therapeutic effects or phases the method 
will be outside the scope of Article 53(c) EPC. For example, regarding a method to 
remove body hair37 the TBA held that it should be considered cosmetic and thus 
patentable since although excess of body hair could be caused by genetic factors or by an 
endocrinology disease, it is not a condition by itself that causes pain or discomfort. The 
only patentable methods are those with technical effects and aesthetic purposes that are 
totally separated and autonomous from any therapeutic effects that they may have.38 In a 
different line of reasoning, in a controversial decision concerning a method for 
improvement of the physical external appearance of any mammal though administration 
of a product with appetite suppressing properties, the TBA has held that it was not 
possible to dissociate the aesthetic effect from the therapeutic effect (obesity treatment) 
but since the claims only sough to obtain patent protection to the aesthetic method (that 
could be applied to both healthy and obese persons/animals) patentability should not be 
denied.39 However it should be noted that this line of reasoning seems to be an exception 
to the general trend. The majority view expressed in EPO decisions such as in General 
Hospital/Hair removal method40 leads to the conclusion that any method claim containing 
both therapeutic and cosmetic results which can not be separated will be denied 
                                                 
30 T-290/86 ICI/Cleaning plaque [1990.11.13] OJ EPO 1992. 
31 T-143/94 Jutta Mai [1995.10.05] OJ EPO 1996. 
32 T-81/84 Rorer/Dysmenorrhea [1987.05.15] OJ EPO 1988. 
33 T-24/91 Thompson/Cornea [1994.05.05] OJ EPO 1991. 
34 T-81/84. 
35 T-582/88 Eli Lilly [1990.05.17], OJ EPO, 1991. 
36 T-74/93 British Technology Group/Contraceptive method [1994.11.09], OJ EPO 1995, and T-820/92 
General Hospital/Contraceptive method [1994.01.11], OJ EPO 1995. However the solution will be 
different if the contraceptive method implies a therapeutic method in the sense that its execution prevents 
associated side effects, in this sense see T-820/92 General Hospital/Contraceptive method [1994.01.11], 
OJ EPO 1995. 
37 T-383/03 General Hospital/Hair removal method [2004.10.01], OJ EPO 2005. 
38  It can be argued that aesthetic imperfections often cause psychic pain and discomfort such as low self 
esteem and social interaction problems. The essential question lays in obtaining an objective valuation and 
measurement of such psychic pain and discomfort that ultimately can establish the distinction between 
enhancement and therapy. Such effects are known to vary to a great extent from individual to individual, 
the legal criteria adopted so far has been based in subjective notions of reasonability and thus can be 
criticised for being artificial and lacking scientific grounds.  
39 T-144/83 Du Pont/appetite suppressant [1986.03.27], OJEPO 1986. 
40 T-383/03. 
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patentability under the  rule of Article 53 (c) EPC. It is also apparent that the delimitation 
of the concept of therapy is an artificial legal creation not fully based in scientific criteria 
and often dependent on circumstantial factors such as the actual phrasing of the claims.41 
 
d) Methods for surgery 
 
 Taking into account the previously mentioned considerations regarding the ratio 
legis and nature of this legal provision, the prohibition concerning surgery methods 
should not be understood as absolute, meaning that the nature of this patentability 
exemption does not seem to imply a prohibition per se of all chirurgical methods, but 
rather only of those that pursue or have as a result therapeutic goals.42 
 The EPO guidelines for examination still maintain that ’Surgery defines the 
nature of the treatment rather than its purpose. Thus, for example, a method of treatment 
by surgery for cosmetic purposes or for embryo transfer is excluded from patentability, 
as well as surgical treatment for therapeutic purposes.’43  However in light of the EBA 
decision on G-1/04 where the EBA held (while defining the interpretation of ought to be 
considered diagnostic methods) that chirurgic methods in the meaning of the EPC are 
any methods that imply physical interventions on the human or animal body, ’in which 
maintaining the life and health of the subject is of paramount importance’44 the provision 
should be understood has only encompassing surgery methods with a therapeutic 
objective or effect such as prevention of diseases or any dysfunction and re-establishing 
the physical or psychic equilibrium of a person (including relief/suppress of pain and 
physical discomfort and restore any body functions/capabilities  even if the diminishing 
was not caused by a disease). Only such interpretation is compatible with the ratio of the 
legal rule, understood has the protection of the freedom of practice of non 
commercial/non industrial activities in the field of human and veterinary medicine.45 
 
3.3 Applying the general rule to Nanotechnology inventions 
 
 Nanotechnology inventions due to their interdisciplinary nature are likely to 
experience all the patentability difficulties previously felt in more classical technological 
fields, that is to say that a nanotechnology invention combining different technological 
fields such as for example biotechnology, biomedicine, and information and 
communication technologies will likely experience all and the same patentability issues 
relevant in those technological field that it encompass. On the other side, there is also 
good news for inventors seeking patent protection: nanotechnology inventions’ hybrid 
                                                 
41 See in this sense Cook, Trevor, op. cit. 
42 In this sense Marques, J. op. cit.. See also Bentley, L and Sherman S., ‘Intellectual Property Law’, 
Oxford University Press, 2001 and Bentley, L and Sherman S., Intellectual Property: Patents, Copyright, 
Trade Marks and Allied Rights, 6 ed. Sweet & Maxwell, London, 2007. 
43 EPO Guidelines 2009 Part C, Chapter IV, 4.8.1. 
44 G-1/04 paragraph 6.2.1. In the same sense see T-35/99 Georgetown University/Pericardial access 
[1999.09.29], OJ EPO 2000, and T-789/96 Ela Medical/Méthode thérapeutique [2001.08.23], OJ EPO 
2002. 
45 G-6/83 Pharmuka/Indication médicale [1984.12.05], OJ EPO 1985. 
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nature means increased flexibility in patent claim drafting and thus increased patent 
strategic options to maximize patent protection and circumvent exclusions and 
exceptions to patentability, for example often it will be possible to describe an invention 
both as an apparatus and a compound.46 
 In theoretical terms, applying the general orientation of the EPO to 
nanotechnology will lead to the conclusion that nanotechnology inventions of a 
therapeutic nature that can only be described as a method claim in principle can be 
patentable. Patentability will not be barred as long as the phases of the method that 
operate in contact with the body do not allow identifying the presence of a symptom but 
merely intermediate results. However this requirement may be difficult to fulfil due to 
the particular nature of nanotechnology.  
 Regarding some of the nanotechnology inventions previously mentioned such as 
nanoparticles delivery systems introduced in the blood stream with the mission to identify 
and repair or destroy, e.g. cancer cells, any inventors IP strategy will most likely 
encompass attempts to obtain patent protection covering as many aspects and 
components of the invention as possible. Such may include attempts to claim the 
nanoparticles delivery system in itself and/or drafting claims for: (1) the nanoparticle 
(that can take many shapes, be composed of different materials such as polymers, lipids, 
carbon nano-tubes or ceramic materials and offer different features that may be 
patentable); (2) the active agent; (3) the targeting moiety (usually small molecule or 
peptide-based).47 In addition nanoparticles delivery systems can be used by patent 
holders in order to extend the life or revitalise patents of active agents by means of second 
medical use patents claims due to nanoscale related advantages over the original active 
agent. Special attention to claim drafting will be required as to avoid both the surgery 
and therapeutic methods prohibitions, in particular while claiming the nanoparticles 
delivery system as a whole. 
 In general, substance or compositions claims and apparatus claims should present 
a safer option as to avoid the patentability exception. While method claims will remain 
particular difficult to obtain in Europe due to the need to circumvent the ‘practiced on 
the human body’ prohibition, in light of the EPO jurisprudence as described previously 
in principle nanodevices or substances if claimed as such should be patentable. A patent 
is merely a monopoly right to commercially explore the invention, e.g. manufacturing 
and making available in the market and does not include the use of the invention by 
medical practitioners, thus patentability of apparatus or substances can not hamper the 
freedom of diagnosis and pursuing a selected medical treatment.  
 Outside the scope of this prohibition are also cosmetic methods, but the 
distinction between what is still therapeutic even if only prophylactic and what can be 
considered cosmetic is not clear, and as observed previously the EPO decisions on the 
matter show some degree of inconsistency. Nanotechnology is expected to add further 
                                                 
46 Zech, Herbert, ‘Nanotechnology – New Challenges for Patent Law?’, 2009 6:1 SCRIPTed 144, available 
at http://www.law.ed.ac.uk/ahrc/SCRIPT-ed/vol6-1/zech.asp (February 2010) 
47 Follett, Angela D. and Lavoie, Teresa A. ‘Delivering macro-quality IP protection for nanosized 
therapeutics’, 5 Nanotechnology L. & Bus. 163, 2008. 
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difficulties since many of the on-going research will lead to inventions that not only are 
meant to restore natural functions and abilities but have the potential to enhance them.  
 In general terms, nanotechnology inventions concerning methods for enhancing 
natural human capabilities (e.g. improving the sense of vision, smell or earring) or 
introduce abilities, functions characteristics not provided by nature in the present 
evolutionary state (e.g. telepathic and telekinetic abilities) should not find objections 
under this provision as it has been interpreted by the EPO. As long as such methods can 
not be considered therapeutic, they should be treated in an analogical way as cosmetic 
methods and thus outside the scope of the prohibition.48 
 In practice in borderline situations it may prove difficult to assert what is 
enhancement and what is restoration of human abilities and functions since those tend to 
vary from individual to individual, possible criteria could be the medical tables for 
subnormal values that implies a medical diagnosis of a certain medical condition e.g. lack 
of vision, anything above those values could be considered enhancement and therefore 
non therapeutic. However the difficulty will remain since under these criteria the same 
invention would be considered either therapeutic or non-therapeutic depending on its 
intended user. Implants in the nervous system that allow the user to communicating 
wireless with computers and exchange nerve signals with other persons is an example of 
a technology being researched that if applied to an individual with mobility and 
communication capability severely reduced it will have as primary objective and effect 
to restore the ability to communicate and interact with the surrounding environment and 
thus it will have to be considered restoration/replacement of natural abilities and thus 
therapeutic, but the same technology when applied to subjects without such impairments 
it will have as effect the introduction of telepathic abilities and will have to be considered 
enhancement. Ultimately patentability will be dependent to a large extent on the 
creativity applied in patent drafting, something that is not new in the patent system but 
nonetheless raises objections from a legal science point of view. 
 
4. Methods for treatment and Diagnosis and the reform of the patent system 
 
 The interdisciplinary nature of nanotechnology appears to advice against specific 
patent legislation, something that could prove difficult in light of the TRIPS Agreement 
and could only be achieved by introducing a Nanotechnology Directive or a similar legal 
instrument clarifying concepts and patentability issues. Furthermore, to introduce such 
legislation would be premature at this point since the technology is still emerging.49 
However, such does not exclude the fact that nanotechnology due to its nature requires 
the revaluation of this exception to patentability, nor that its overall increasing social-
economic relevance cannot be overlooked and will became a contributing factor for such 
need.  
                                                 
48 However, it is not excluded objections raised under the general ‘ordre public’ and morality exception to 
patentability of Article 53 EPC. See for further analysis Nordberg, A. ’Nanotechnology patents in Europe: 
Exclusions and Exceptions to patentability’, Stockholm University, Jan.2010. Available at: 
http://www.juridicum.su.se/juruppsatser/2010/ht_2010_Ana_Rita_Nogueira_de_Sousa_Branquinho_Nor
dberg.pdf (February 2010). 
49 In this sense  Zech, H. op.cit. 
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 If the nature, ratio and maintenance of this prohibition have long been subject to 
intense debate, such interrogations are becoming increasingly important and accurate in 
light of the recent scientific advances in fields such as nanomedicine and 
nanobiotechnology. 
 Among European scholars, many do not favour the maintenance of this exception 
to patentability in its current formulation,50 and legal practitioners have since long used 
creative claim drafting to avoid an entire industry to fall into the scope of the 
prohibition,51 which from a legal science perspective is always a sign of de-
synchronization between law and the social reality.  
 The issue is complex due to the delicate nature of the interests being balanced and 
thus further research and public debate is needed in this field and the projected reform of 
the patent system that recently shown some progress52 can provide an excellent 
opportunity for both. 
 The act of attributing a patrimonial right (e.g. patent) is in nature different and 
should not be confused with the act of attributing (or denying) effective and un-restricted 
economic and industrial exploitation of such patrimonial right. The patent right should 
be understood as a mainly neutral legal institute, in the sense that it is outside its scope 
regulating the development of certain research activities, or the possibility and forms of 
commercial and industrial exploitation of an invention.  
 Patent law ultimate goal and primary function should be to promote and reward 
scientific research and technological and industrial innovation by determining which 
inventions can be commercially and industrially explored in a regimen of monopoly for 
a certain period of time (currently twenty years). In this sense exceptions to patentability 
should be narrowly constructed, carefully accompanying the evolution of the legal 
system and in close connection with scientific progress and social evolution. Allowing 
patent protection, i.e. a monopoly right for commercial exploitation, provides incentive 
                                                 
50 See among others Beier, Freidrich-Karl, ‘Future Problems of Patet Law’ in International Review of 
Industrial Property and Copyright Law, 1972; Bergmans, Bernhard, ‘La Protection des Innovations 
Biologiques- Une Etude de droit comparé, Maison Larcier, Brussels 1991; Moufang, Rainer, ‘Methods of 
medical treatment under patent law’ in International Review of Industrial Property and Copyright Law, 
Vol. 24 No 1/1993; Thums, Doris, ‘Patent Protection for Medical Treatment a distintion between patent 
and medical law’, International Review of Industrial Property and Copyright Law, Vol. 27, No. 4/1996; 
Domeij, Bengt ‘Pharmaceutical Patents in Europe’, Norstedts Juridik, Stockholm 2000; Thomas, Daniel 
X. ‘Patentability Problems in Medical Technology’, in International Review of Industrial Property and 
Copyright Law, 2003; Marques, J.P. Remédios, ‘A patentabilidade dos Métodos de diagnóstico…’ op.cit.; 
Cook, Trevor ‘Pharmaceuticals Biotechnology and the Law’ op. cit. 
51 A known example is the use of Swiss-type claims ‘Use of a substance or composition X for the 
manufacture of a medicament for treatment of disease or condition Y’ in order to obtain patent protection 
for pharmaceuticals. 
52 Recently, during the Swedish Presidency of the EU a breakthrough in negotiations was achieved pursuant 
to the 2982nd Competitiveness meeting of the EU Council that concluded over the creation of a European 
and EU Patents Court (EEUPC), an EU patent, including the separate regulation on the translation […], 
an Enhanced Partnership between the European Patent Office and central industrial property offices of 
Member States and, to the extent necessary, amendments to the European Patent Convention’  , and the 
accession of the EU to the EPC. See Council of the European Union ’Conclusions on an enhanced patent 
system in Europe’ 2982nd Competitiveness (Internal market, Industry and Research) Council meeting, 
Brussels, 4 December 2009, paragraph 4. 
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not only for further research but also and most relevantly in this complex technological 
field provides incentive for the disclosure of the invention.  
 Given the above mentioned function of the patent system, the patentability 
exception of Methods for treatment and Diagnosis has always been difficult to justify. 
The exception was initially constructed has an exclusion based in a lack of industrial 
application, and later was framed in Article 53 (c) pursuant to the EPC Revision in 2000 
and as discussed previously, its nature and ratio legis is still largely debated. Currently 
the ratio legis of this prohibition is anchored in the need to protect and assure therapeutic 
freedom to medical practitioners, and the universal right to access medical care. The main 
argument, still subsisting as justification for the prohibition is that allowing the 
patentability of such methods would imply that medical practitioners would be forced to 
pay royalties and thus hampering their therapeutic freedom. However, such does not 
seem convincing as it has been for long considered acceptable to pay the patent holder 
royalties included in the price of pharmaceutical products and apparatus for clinical use 
such as machines and instruments, without the patentability of those apparatus ever being 
doubted for ‘ordre public’ and morality reasons.53 Further one has to take into 
consideration that the prohibition does not exist in all patent systems and such 
international patent law lack of harmonization creates difficulties and legal uncertainty. 
For example, in the USA patent law there is no correspondent patentability prohibition 
of therapeutic and diagnostic methods, medical practitioners are exempted from patent 
infringement as long as the performance of the patented method occurs during the 
exercise of a medical activity54 and notably litigation opposing patent holders for 
therapeutic and diagnostic methods and health care professionals is relatively 
uncommon.  Leading to consider from a de jure condendo perspective, whether it should 
not be preferable to erase this exception to patentability and introduce either a similar 
solution or other correction mechanisms to protect the interest of public health such as 
(a) compulsory license mechanisms;55 (b) Establish a experimental use exception; or (c) 
Use public regulatory instruments such as market authorizations similar to those existing 
for pharmaceutical products to maintain accessibility to these products.  
  Nanotechnology inventions blur the already thin line between what can and what 
can not be considered for legal purposes of the patentability exception a method for 
treatment and diagnosis applied to the human body. Nanotechnology inventions 
including those that could fit into the prohibition, unlike traditional therapeutic/diagnosis 
methods are no longer a by-product of the medical praxis, a result of ‘accidental’ findings 
by a single medical practitioner, but rather require considerable investment in specialized 
equipment and the full time work of scientific multidisciplinary research teams. Nano-
medicine research activities consume considerable time and financial resources and the 
inventions in this field are the result of prolonged research frequently conducted by 
multidisciplinary teams meaning that professional and scientific acknowledgment, e.g. 
                                                 
53 Domeij, Bengt ‘Pharmaceutical Patents in Europe’, 2000, Chapter 1. 
54 §287 (c) (1) (4) USA Patents Act. 
55 Compulsory licences are already established in general terms in the projected European patent regulation, 




through publishing the findings in scientific publications, is no longer a suitable incentive 
for an enabling disclosure. Under this line of reasoning the patentability exclusion not 
only is no longer achieving its objectives of promoting the development of new medical 
methods of treatment and providing for universal accessibility to state of the art medical 
care, but is in fact becoming a hampering factor.56  
 As mentioned it remains a matter for discussion if the solution adopted in the 
European patent system is in fact the most appropriate to accomplish in simultaneous the 
objectives of: (1) protecting the freedom of the medical practitioner to perform on  their 
patients all known (state of the art) methods for treatment and diagnosis that they deem 
appropriate; (2) the right of the patient to receive any methods for treatment and diagnosis 
available, appropriate and efficient for his/her condition and; (3) the need to promote 
innovation and scientific research, i.e. though an adequate reward system.  
 The argument, that allowing the patentability of such methods would imply that 
medical practitioners would be forced to pay royalties and thus hampering their 
therapeutic freedom is not convincing if we consider that: (a) It has been for long 
considered acceptable to pay the patent holder royalties included in the price of 
pharmaceutical products and apparatus for clinical use such as machines and instruments, 
without the patentability of those apparatus ever being doubted for ‘ordre public’ and 
morality reasons; and (b) The evidence found in the example of other patent systems 
where such prohibition does not exist reinforces the conviction that other legislative 
solutions are in fact possible. Another recurrent argument lays in the protection of public 
interest: it is often commented in the political rhetoric that lifting the patentability 
prohibition would increase the cost of  the health care systems and further increase the 
financial burden that public health care systems imposes on public finances. Such 
argument losses credibility if corrective legislative measures, such as for example the 




 At this point to maintain a general prohibition clause that leads to artificial legal 
constructions in order to (continue to) keep outside the scope of the provision the 
pharmaceutical industry, something that may become increasable difficult as scientific 
advances further blur the line between what may or not fall under the exception, appears 
to be incompatible with the general objectives of improving the competitiveness of 
European industry, promoting scientific research and industrial innovation, and 
strengthen the mechanisms and dynamics of transforming scientific advances into new 
products available in the market that can benefit the overall society by providing for 
universal accessibility to state of the art medical care. 
 The projected reform of the patent system and the introduction of a European 
patent provide for a forum for debate and an opportunity for re-thinking this patentability 
issue and consider whether it should not be preferable to allow patentability and 
simultaneously introduce legal mechanisms to either: (1) Exempt medical practitioners 
from patent infringement as long as the performance of the patented method occurs 
                                                 
56 In similar sense regarding biotechnological inventions Domeij, B. op. cit. 
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during the exercise of a medical activity; (2) Make use of compulsory license 
mechanisms; (3) Establish a experimental use exception; and/or (4) Use public regulatory 
instruments such as market authorizations similar to those existing for pharmaceutical 
products to maintain accessibility to these products. 
 The projected reform of the patent system so far has not contemplated any 
changes concerning this exception to patentability, however this is a complex and most 
important issue as any legislative option (including maintaining the current formulation) 
needs to maintain a balance between delicate and most relevant public interests, such 
means that these matters need to continue to be object to public debate and further legal 
science research.  
 
 
 
 
